Why Metsera's Share Price Is Plummeting This Week
Innovative biopharmaceutical company Metsera (NASDAQ: MTSR) has been climbing all year. It went public on Feb. 3 of this year, priced at $18 per share, and immediately climbed above $27. It had been rising higher all year and closed above $83 on Friday, Nov. 7, a high for the stock.
But on Monday of this week, it plummeted below $71, a 15% drop in a day. What's going on?
The big news for Metsera in recent weeks was a bidding war for the company between drug giants Novo Nordisk (NYSE: NVO) and (NYSE: PFE). One of the biggest and most rapidly growing markets for pharmaceutical companies today is the GLP-1 market, with drugs that effectively treat type 2 diabetes and obesity.
Source Fool.com
Pfizer Inc. Aktie
23,10 €
-0,58 %
Leichte Buy-Präferenz bei der Pfizer Inc. Aktie.
Ein positives, wenn auch nicht starkes, Potenzial für Pfizer Inc. mit einem Kursziel von 27 € im Vergleich zu 23.1 €.
